{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2026:BM3FJDXDFVHX3LMUWQNLHRP3GL","short_pith_number":"pith:BM3FJDXD","schema_version":"1.0","canonical_sha256":"0b36548ee32d4f7dad94b41ab3c5fb32d2569f68df1f8d8c5f6b9652e2d87866","source":{"kind":"arxiv","id":"2607.17692","version":1},"attestation_state":"computed","paper":{"title":"A Globally Calibrated Bayesian Optimal Phase II Design for Adaptive Enrichment Trials","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Hisato Sunami, Masaaki Kuriki, Masahiro Kojima","submitted_at":"2026-07-20T08:40:33Z","abstract_excerpt":"Adaptive enrichment can allow the development of an experimental treatment to continue when its activity is insufficient in an all-comer population but remains promising in a prespecified biomarker-positive subgroup. However, a straightforward sequential application of separately calibrated phase II designs to the two populations can inflate the probability of a false-positive efficacy conclusion. The Bayesian optimal phase II (BOP2) design uses posterior-probability thresholds for interim futility monitoring and final efficacy decisions in single-arm phase II trials. We develop a pathwise glo"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2607.17692","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2026-07-20T08:40:33Z","cross_cats_sorted":[],"title_canon_sha256":"0028bb4420fd00d7cd5189d45c49a290575f530391c89c1975fa4525d154730b","abstract_canon_sha256":"d14981f0f9a9c7a3dd6a596c312915de090c94d4f40cfe2d8f1b1d931adaef55"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-21T02:21:54.929529Z","signature_b64":"VOjJzPLY7aM0XY4wreeni7IdBwZLeSf7hnsVCLfsWXY9rlWhFtXPa7y+zWM7SrKEYp8rrWzPEmATdJpGHpegDg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"0b36548ee32d4f7dad94b41ab3c5fb32d2569f68df1f8d8c5f6b9652e2d87866","last_reissued_at":"2026-07-21T02:21:54.928653Z","signature_status":"signed_v1","first_computed_at":"2026-07-21T02:21:54.928653Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"A Globally Calibrated Bayesian Optimal Phase II Design for Adaptive Enrichment Trials","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Hisato Sunami, Masaaki Kuriki, Masahiro Kojima","submitted_at":"2026-07-20T08:40:33Z","abstract_excerpt":"Adaptive enrichment can allow the development of an experimental treatment to continue when its activity is insufficient in an all-comer population but remains promising in a prespecified biomarker-positive subgroup. However, a straightforward sequential application of separately calibrated phase II designs to the two populations can inflate the probability of a false-positive efficacy conclusion. The Bayesian optimal phase II (BOP2) design uses posterior-probability thresholds for interim futility monitoring and final efficacy decisions in single-arm phase II trials. We develop a pathwise glo"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2607.17692","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2607.17692/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2607.17692","created_at":"2026-07-21T02:21:54.929110+00:00"},{"alias_kind":"arxiv_version","alias_value":"2607.17692v1","created_at":"2026-07-21T02:21:54.929110+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2607.17692","created_at":"2026-07-21T02:21:54.929110+00:00"},{"alias_kind":"pith_short_12","alias_value":"BM3FJDXDFVHX","created_at":"2026-07-21T02:21:54.929110+00:00"},{"alias_kind":"pith_short_16","alias_value":"BM3FJDXDFVHX3LMU","created_at":"2026-07-21T02:21:54.929110+00:00"},{"alias_kind":"pith_short_8","alias_value":"BM3FJDXD","created_at":"2026-07-21T02:21:54.929110+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL","json":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL.json","graph_json":"https://pith.science/api/pith-number/BM3FJDXDFVHX3LMUWQNLHRP3GL/graph.json","events_json":"https://pith.science/api/pith-number/BM3FJDXDFVHX3LMUWQNLHRP3GL/events.json","paper":"https://pith.science/paper/BM3FJDXD"},"agent_actions":{"view_html":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL","download_json":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL.json","view_paper":"https://pith.science/paper/BM3FJDXD","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2607.17692&json=true","fetch_graph":"https://pith.science/api/pith-number/BM3FJDXDFVHX3LMUWQNLHRP3GL/graph.json","fetch_events":"https://pith.science/api/pith-number/BM3FJDXDFVHX3LMUWQNLHRP3GL/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL/action/timestamp_anchor","attest_storage":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL/action/storage_attestation","attest_author":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL/action/author_attestation","sign_citation":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL/action/citation_signature","submit_replication":"https://pith.science/pith/BM3FJDXDFVHX3LMUWQNLHRP3GL/action/replication_record"}},"created_at":"2026-07-21T02:21:54.929110+00:00","updated_at":"2026-07-21T02:21:54.929110+00:00"}